HistoSonics introduced final week that its Edison histotripsy system for noninvasively destroying liver tumors has secured restricted U.Ok. market entry.
In response to the Plymouth, Minn.–based mostly firm, the Medicines and Healthcare Merchandise Regulatory Company in Nice Britain granted managed early restricted market entry below an Unmet Scientific Want Authorisation out there by way of the U.Ok.’s Revolutionary Units Entry Pathway (IDAP) program.
The Edison system was one in every of simply eight out there utility spots in 2024, HistoSonics stated.
“Securing GB-controlled entry by way of the IDAP pilot program is an incredible milestone for HistoSonics and indicators clear recognition of our expertise’s potential to rework healthcare,” said HistoSonics CEO Mike Blue. “We’re honored to work alongside the NHS and U.Ok. regulatory and entry companions to deliver histotripsy to sufferers throughout the U.Ok., lots of whom have restricted choices. This progress builds on our robust scientific monitor report within the U.S. and our rising base of scientific proof globally.”
The Monetary Occasions reported final month that HistoSonics is contemplating a possible sale after receiving a number of presents from main medical expertise corporations.
Edison makes use of ultrasound vitality to focus on tumors
The Edison system makes use of centered ultrasound vitality to offer histotripsy remedy. Delivered through a robotic arm, the non-thermal, non-invasive centered ultrasound expertise mechanically destroys and liquifies focused tissue and tumors, with out the invasiveness or toxicity of conventional procedures.
HistoSonics famous that physicians who’ve accomplished firm-provided coaching ought to solely use the machine. The scientific judgment of a professional and appropriately educated doctor ought to all the time information its use, it added.
Edison obtained de novo clearance from the U.S. Meals & Drug Administration in October 2023.
HistoSonics will get first insurance coverage protection
Additionally final month, HistoSonics secured its first main insurance coverage protection for Histotripsy. Blue Cross Blue Defend of Michigan (BCBSM) and Blue Care Community created a brand new medical coverage for histotripsy of the liver. The coverage covers non-thermal histotripsy utilizing the Edison Histotripsy System for the therapy of main and metastatic liver tumors.
This implies, as of Feb. 1, 2025, histotripsy is a reimbursable process for the non-invasive mechanical destruction of liver tumors below CPT code 0686T. This offers eligible sufferers in Michigan early entry to this incisionless therapy forward of the broader coverage’s efficient date of July 1.
So far, greater than 50 main medical facilities throughout the U.S. have adopted the Edison Histotripsy System. Surgeons, radiologists, and oncologists have used it to deal with over 1,500 sufferers, claimed HistoSonics.
Editor’s observe: This text was syndicated from The Robotic Report sibling website MassDevice.
Now accepting session submissions!
